Histone deacetylase inhibitors in multiple myeloma

Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-enviro...

Full description

Saved in:
Bibliographic Details
Published inHematology reports Vol. 1; no. 1; pp. 9 - e9
Main Authors Deleu, Sarah, Menu, Eline, Van Valckenborgh, Els, Van Camp, Ben, Fraczek, Joanna, Vande Broek, Isabelle, Rogiers, Vera, Vanderkerken, Karin
Format Journal Article
LanguageEnglish
Published Pavia MDPI AG 03.06.2009
PAGEPress Publications
Subjects
Apoptosis
Bone marrow
Bortezomib
Chemotherapy
Clinical trials
Drug resistance
Histone deacetylase
Immunosuppressive agents
Multiple myeloma
Stem cell transplantation
Tumor cells
Online AccessGet full text

Cover

More Information
Summary:Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.
ISSN:2038-8322
2038-8330
1970-6790
DOI:10.4081/hr.2009.e9